Payment overview · 2025
General Payments
$1,376.89
64 reported records · 23 companies
Healthcare provider profile · identity verified
Amy C Campion, DO
Allopathic & Osteopathic Physicians|Family Medicine · LEE, MA · NPI 1548352073
Verified facts
What the public records show
CMS Open Payments records show Amy C Campion, DO received $1,376.89 in general payments during 2025 across 64 reported records.
Lundbeck LLC accounted for 11.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $159.62 | 11.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $118.47 | 8.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $114.92 | 8.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.39 | 8.1% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $106.60 | 7.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.40 | 6.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.19 | 6.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $87.95 | 6.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.95 | 4.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.26 | 4.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $56.28 | 4.1% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $55.12 | 4.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.13 | 3.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.84 | 2.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.23 | 1.8% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.84 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.77 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.52 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.52 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.56 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.74 | 1.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.93 | 1.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $13.66 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,376.89 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $159.62 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $106.60 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $87.95 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.95 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.75 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $60.51 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $59.44 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.02 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.72 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.05 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.05 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.13 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 36 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 319 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 53 |
| Omeprazole | Omeprazole | 234 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 201 | 54 |
| Lorazepam | Lorazepam | 179 | 55 |
| Gabapentin | Gabapentin | 164 | 30 |
| Losartan Potassium | Losartan Potassium | 150 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 38 |
| Trazodone Hcl | Trazodone Hcl | 123 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 29 |
| Famotidine | Famotidine | 117 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 31 |
| Furosemide | Furosemide | 95 | 18 |
| Sertraline Hcl | Sertraline Hcl | 95 | 21 |
| Simvastatin | Simvastatin | 91 | 24 |
| Metformin Hcl | Metformin Hcl | 90 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 20 |
| Eliquis | Apixaban | 68 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 28 |
| Valacyclovir | Valacyclovir Hcl | 62 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 51 |
| Prednisone | Prednisone | 61 | 33 |
| Alendronate Sodium | Alendronate Sodium | 56 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Potassium Chloride | Potassium Chloride | 48 | suppressed |
| Alprazolam | Alprazolam | 44 | 18 |
| Atenolol | Atenolol | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Ozempic | Semaglutide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Gemtesa | Vibegron | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Spironolactone | Spironolactone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,376.89 · 64 records | Lundbeck LLC | ABILIFY ASIMTUFII, ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, GEMTESA, IBSRELA, KISUNLA, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VRAYLAR, VYKAT XR, Veozah, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error